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Background: Each year more than two million people are newly infected with HIV worldwide, a majority of them
through unprotected vaginal sex. More than half of new infections in adults occur in women. Male condoms and
male circumcision reduce the risk of HIV acquisition; but the uptake of these methods is out of the control of
women. We therefore aimed to determine the effectiveness of vaginal microbicides (a potential female-controlled
method) for prevention of sexual acquisition of HIV in women.
Methods: We conducted a comprehensive search of peer-reviewed and grey literature for publications of
randomised controlled trials available by September 2012. We screened search outputs, selected studies, assessed
risk of bias, and extracted data in duplicate; resolving differences by discussion and consensus.
Results: We identified 13 eligible trials that compared vaginal microbicides to placebo. These studies enrolled
35,905 sexually active HIV-negative women between 1996 and 2011; in Benin, Cameroon, Cote d’Ivoire, Ghana,
Kenya, Malawi, Nigeria, South Africa, Tanzania, Uganda, Zambia, Zimbabwe, India, Thailand, and the United States of
America. A small trial of 889 women found that tenofovir (a nucleotide reverse transcriptase inhibitor) significantly
reduces the risk of HIV acquisition (risk ratio [RR] 0.63, 95% confidence intervals [CI] 0.43 to 0.93). Effectiveness
data are not yet available from follow-up tenofovir trials being conducted in South Africa, Uganda, and Zimbabwe
(1 trial) and multiple sites in South Africa (1 trial). We found no evidence of a significant effect for nonoxynol-9
(5 trials), cellulose sulphate (2 trials), SAVVY (2 trials), Carraguard (1 trial), PRO 2000 (2 trials), and BufferGel (1 trial)
microbicides. The pooled RR for the effect of current experimental vaginal microbicides on HIV acquisition in
women was 0.97, 95%CI 0.87 to 1.08. Although study results were homogeneous across the different drug classes
(heterogeneity P = 0.17, I2 = 27%), the overall intervention effect was not statistically significant. Nonoxynol-9
significantly increased the risk of having adverse genital lesions but no other microbicide led to significant
increases in adverse events.
Conclusions: There is not enough evidence at present to recommend vaginal microbicides for HIV prevention.
Further high-quality research is needed to confirm the beneficial effects of tenofovir as well as continue the
development and testing of new microbicides.* Correspondence: obierojatina@yahoo.com
1Department of Reproductive Health and Biology, Institute of Primate
Research, Karen Road, Nairobi, Kenya
2Department of Medical Microbiology, University of Nairobi, Off Ngong Road,
Nairobi, Kenya
Full list of author information is available at the end of the article
© 2012 Obiero et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Obiero et al. BMC Infectious Diseases 2012, 12:289 Page 2 of 8
http://www.biomedcentral.com/1471-2334/12/289Background
Antiretroviral drugs are among the greatest medical
breakthroughs of the last three decades. However, they
have limitations which include (but are not limited
to) the emergence of multi-drug-resistant HIV virus
strains, toxicity, difficult treatment regimens, and inad-
equate pharmacology, bioavailability and tissue distribu-
tion [1-3]. Therefore, prevention of new HIV infections
remains the backbone of efforts to control the HIV pan-
demic [1,4,5]. The male condom protects against acqui-
sition and transmission of HIV, but its use requires
agreement by both sexual partners. Recently, early initi-
ation of antiretroviral therapy was shown to be effective
in reducing the risk of sexual transmission of HIV [6]. In
addition medical male circumcision reduces the risk of
HIV acquisition in men [7,8], but evidence is lacking on
whether male circumcision confers protection for
women; who currently account for more than half of the
34 million people estimated to be living with HIV world-
wide [1]. The need for female-controlled HIV prevention
strategies has been recognised, and the current strategies
being researched include vaginal microbicides [9].
Microbicides are compounds that when inserted vagi-
nally would (at least in theory) act to prevent acquisition
and or transmission of HIV during sexual intercourse.
Most of the current microbicide research is undertaken
in sub-Saharan Africa and Southeast Asia, but an effect-
ive microbicide will undoubtedly be used worldwide to
prevent the sexual acquisition and or transmission of
HIV. It has been estimated that even a partially effective
microbicide could prevent millions of new HIV infec-
tions each year throughout the world [10]. In the
absence of an effective prophylactic HIV vaccine, the de-
velopment of a safe and effective microbicide is critical.
This review aimed to determine the effectiveness of vagi-
nal microbicides in preventing sexual acquisition of HIV
infection by women.
Methods
We undertook this systematic review according to stand-
ard Cochrane methods [11]. We conducted a compre-
hensive search of electronic databases for relevant
randomised controlled trials and systematic reviews pub-
lished by September 2012. The databases searched were
the Cochrane Central Register of Controlled Trials
(CENTRAL), Medline, Embase, Web of Science, NLM
Gateway, AIDS Education Global Information System,
ClinicalTrials.gov, the World Health Organization
(WHO) International Clinical Trials Registry Platform,
Cochrane Database of Systematic Reviews (CDSR), and
York Database of Abstracts of Reviews of Effectiveness
(DARE). We supplemented the search by screening
bibliographies of identified articles and proceedings of
international AIDS conferences, and contacting relevantexperts at WHO and the Joint United Nations
Programme on HIV/AIDS (UNAIDS). We searched
for all relevant studies regardless of language or publica-
tion status.
Two authors (Jael Obiero and Charles Wiysonge) in-
dependently assessed study eligibility, risk of bias in
included studies, and extracted data; with disagreements
resolved by discussion and consensus. Eligible studies
were randomised controlled trials in which sexually ac-
tive HIV-negative women from any setting were ran-
domly allocated to a vaginal microbicide compared to a
placebo or no intervention. All included studies were
approved by relevant institutional ethical review boards
in specific countries and all participants provided written
informed consent. We have summarised the search and
selection process for this review in Figure 1.
Our outcome of interest was new HIV infection; deter-
mined using internationally accepted diagnostic criteria.
We used the Cochrane Collaboration’s Review Man-
ager 5.1 (http://ims.cochrane.org/RevMan) for statistical
analyses. We expressed each study result as a risk ratio
(RR) with its 95% confidence intervals (CI) and con-
ducted meta-analysis by analysing trial participants in
groups to which they were randomised, regardless of
which or how much treatment they actually received.
Despite the excellent mathematical properties of the
odds ratio (OR), we did not choose it to measure study
results in our analyses because the OR and RR differ
considerably when control group risks are high (as was
the case in this review) and effects are large. A misinter-
pretation of the OR in such a situation would lead to an
overestimation of the intervention effect. There exist
published examples of situations where authors have
misinterpreted the OR from meta-analyses as if they
were RR, leading to overestimation of intervention
effects [11].
In meta-analyses, it is important to measure the degree
to which the results of studies are consistent. Inconsist-
ency in study results, known as statistical heterogeneity,
is a consequence of clinical and or methodological dif-
ferences among studies. Statistical heterogeneity mani-
fests itself in the observed treatment effects being more
different from each other than one would expect due to
random error (or chance) alone. We used the Cochran’s
Q test to assess statistical heterogeneity between study
results, defining statistical significance at the 10% alpha
level [11,12]. Q is a chi-squared statistic with “degrees of
freedom” equals to “number of studies” minus 1. The
statistic is calculated as the weighted sum of the squared
differences between individual study effects and the
pooled effect across the included studies, with the
weights defined by the model of meta-analysis used i.e.
fixed effect or random-effects. Q assesses whether
observed differences in results are compatible with
Identified through comprehensive search
N = 5572 records
Titles and abstracts screened Clearly irrelevant records excluded
N = 5572 N = 5550
Full-text articles reviewed for eligibility
N = 22
Excluded studies: 7 studies
- Study with non-HIV outcomes(N=6)
- Study which enrolled only HIV 
positive women (N=1)
Ongoing studies:
N = 2
Studies included in review
N = 13
Figure 1 Flow chart of identification and selection of studies for inclusion.
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istic relative to its degrees of freedom) provides evidence
of significant statistical heterogeneity of intervention
effects [11,12]. In addition, we used the Higgins’ I-
squared test to quantify inconsistency in the effects of
microbicides across the studies included in the meta-
analysis [13]. The I-squared test statistic describes the
percentage of the variability in effect estimates that is due
to true differences between studies rather than chance.
There was no significant statistical heterogeneity be-
tween trial results (X2 = 17.72 [13 degrees of freedom],
P = 0.17; I2 = 27%), and we combined the results using
fixed effect meta-analysis [11,12]. However we also con-
ducted a random-effects meta-analysis [14], in order to
document the robustness of our findings to the method
of meta-analysis [11]. The pooled effect from the fixed-
effect method is considered to be a typical intervention
effect from the studies included in the meta-analysis; im-
plying that observed differences among study results are
caused exclusively by chance. Random-effects meta-ana-
lysis, on the other hand, assumes that estimated study
effects are not identical; but differ at random, following
a normal distribution [14]. In addition, we sub-grouped
the trials by type of microbicide under investigation.
Results
Of 22 potentially eligible studies, 13 met our inclusion cri-
teria [15-27] and two are ongoing [28,29]. The remaining
seven studies were excluded; six of them enrolled HIV-
negative women but did not report HIV incidence [30-35]and the seventh one enrolled only HIV positive women
[36]. The seven excluded trials were set up to assess the
effects of vaginal microbicides on the incidence of non-
HIV sexually transmitted infections [30-36].
The 13 included randomised controlled trials, involv-
ing seven microbicides, had either been conducted to
term (three Nonoxynol-9, one BufferGel and 0.5% PRO
2000, one Carraguard, and one tenofovir trial) or
stopped early due to safety concerns (one Nonoxynol-9
and two cellulose sulphate trials) or insufficient rate of
HIV infection and low likelihood of showing a protective
effect (one Nonoxynol-9, one 2% PRO 2000, and two
SAVVY trials) (Table 1). The studies enrolled 35,905
sexually active HIV negative women between 1996 and
2011; in Kenya [15,19], Cameroon [16,17], Cote d’Ivoire
[18], Benin [18,24], Ghana [23], Malawi [26], Nigeria
[20,21], South Africa [17,22,24-27], Tanzania [22], Uganda
[22], Zambia [22,26], Zimbabwe [26], Thailand [18], India
[24], and the United States of America [26].
A small proof-of-concept randomised controlled trial
found that tenofovir (a nucleotide reverse transcriptase
inhibitor) significantly reduces the risk of HIV acquisi-
tion (889 women: RR 0.63, 95% CI 0.43 to 0.93). Despite
the small sample size, the results were statistically sig-
nificant (P = 0.02) [25]. Effectiveness data are not yet
available from the second tenofovir trial that enrolled
5000 women (in South Africa, Uganda, and Zimbabwe)
and was stopped early due to low likelihood of showing
a protective effect [28]. Two of the five arms in this trial
were designed to test the effectiveness of the tenofovir
Table 1 A summary of characteristics of included studies
Author Method Participants and settings Interventions/control
Kreiss 1992 [15] Unblinded RCT 138 female sex workers Nairobi, Kenya 1000 mg N-9 sponge/placebo
Richardson 2001 [19] Double blind RCT 278 female sex workers, Mombasa, Kenya 52.5 mg N-9 gel/placebo
Roddy 1998 [17] Double blind RCT 1292 female sex workers, Cameroon 70 mg N-9 film/placebo
Roddy 2002 [16] Unblinded RCT 1251 women (non sex workers) from clinics or
pharmacy, Cameroon
100 mg N-9 gel/No intervention
Van Damme 2002 [18] Triple blind RCT 892 women sex workers from Benin, Cote d’Ivoire,
South Africa, Thailand
52.5 mg N-9/placebo
Halpern 2008 [21] Double blind RCT 1644 women from bars, market, other common
gathering areas, Lagos and Port Harcourt, Nigeria
6% CS gel/placebo
Van Damme 2008 [24] Double blind RCT 1428 women, South Africa, Uganda, Benin and
India (Chennai, Bangalore)
6% CS gel/placebo
Felblum 2008 [20] Double blind RCT 2153 women from local market areas, bars hostels,
military barracks and colleges, Lagos and Ibadan,
Nigeria
1.0% C31G (SAVVY) gel/placebo
Peterson 2007 [23] Double blind RCT 2142 women from high HIV transmission areas
including markets, bars, hotels, Accra and Kumasi,
Ghana
1% C31G (SAVVY) gel/placebo
Skoler-Karpoff 2008 [27] Double blind RCT 6,202 women from local health clinics, malls, churches,
taxi ranks, other community venues, University of Cape
Town, University of Limpopo-Medunsa campus
Ga-Rankuwa and Medical Research Council, Durban,
South Africa
Carraguard gel/placebo
Abdul Karim 2011[26] RCT Double blind 3101 women in Malawi, South Africa, Zambia , Zimbawe,
USA
BufferGel/ 0.5% PRO2000/placebo
McCormack 2010 [22] RCT Double blind 6,651 women, three sites in South Africa; Mwanza,
Tanzania; Entebbe, Uganda; Mazambuka, Zambia
0.5% PRO2000 gel/placebo
Abdul Karim 2010 [25] RCT Double blind 1085 at urban and rural clinic, Kwa-Zulu Natal,
South Africa
1% tenofovir gel/placebo
CS, cellulose sulphate; N-9, nonoxynol-9; RCT, randomised controlled trials; USA, United States of America.
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trial started in October 2011, with data collection
expected to end in May 2014 [29]. The latter is planned
to assess the safety and effectiveness of 1% tenofovir gel
among approximately 2900 sexually active women at
high risk for sexual acquisition of HIV in South Africa.
We found no evidence of a significant effect on HIV
acquisition for nonoxynol-9 (5 trials, N = 3592; RR 1.13,
95% CI 0.91 to 1.14; [15-19]), cellulose sulphate (2 trials,
N = 3,069: RR 1.20, 95% CI 0.74 to 1.95; [21,24]), SAVVY
(2 trials, N = 4,295: RR 1.38, 95% CI 0.79 to 2.41;
[20,23]), Carraguard (1 trial, N = 6,202: RR 0.89, 95% CI
0.71 to 1.11; [27]), PRO 2000 (2 trials, N = 12,486: RR
0.93, 95% CI 0.77 to 1.14, [22,26]), and BufferGel (1 trial,
N = 1,546: RR 1.05, 95% CI 0.73 to 1.52; [26]) (Figure 2).
The pooled RR for the 13 trials was 0.97 (95% CI 0.87
to 1.08) when we used fixed effect meta-analysis,
and 0.98 (95% CI 0.86 to 1.12) when we used the
random-effects method. Although the confidence inter-
vals were wider with the random-effects method, the
findings of our review are not sensitive to the method of
meta-analysis.
The most common adverse event reported by trials was
genital lesion (laceration, abrasion, ulceration, irritation)with the highest risk occurring in the nonoxynol-9 trials
(5 trials, N = 3592). In the other trials this event was
reported to be similar in both the microbicide and pla-
cebo arms.
The randomisation sequence was adequately generated
and the allocation was adequately concealed in all 13
studies. We therefore think there was no selection bias
in any of the included studies. In two studies [15,16]
blinding was not done since an appropriate placebo
could not be manufactured; hence high risk of bias.
Seven trials [15,19-24] were stopped early due to data-
dependent processes. Due to the early discontinuation,
four of the studies had a very high attrition rate: 10% in
a cellulose sulphate trial [24], 16% in a SAVVY trial [23],
17% in a nonoxynol-9 trial [15], and 30% in another
cellulose sulphate trial [21]. In addition, loss to follow
up was high in three nonoxynol-9 trials conducted to
term i.e. 12% in the trial by Rody and colleagues among
non-sex workers in Cameroon [16], 20% in the trial by
Rody and co-workers among female sex workers in
Cameroon [17], and 22.6% in a trial by Van Damme and
co-workers among female sex workers in Benin, Cote
d’Ivoire, South Africa and Thailand [18]. We have rated
the risk of bias due to incomplete outcome data for each
Study or Subgroup
1.1.1 Nonoxynol 9
Kreiss 1992
Richardson 2001
Roddy 1998
Roddy 2002
Van Damme 2002
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 2.63, df = 4 (P = 0.62); I² = 0%
Test for overall effect: Z = 1.08 (P = 0.28)
1.1.2 Cellulose sulphate
Halpern 2008
Van Damme 2008
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 1.74, df = 1 (P = 0.19); I² = 43%
Test for overall effect: Z = 0.73 (P = 0.46)
1.1.3 SAVVY
Feldblum 2008
Peterson 2007
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 1.28, df = 1 (P = 0.26); I² = 22%
Test for overall effect: Z = 1.13 (P = 0.26)
1.1.4 Carraguard
Skoler-Karpoff 2008
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
1.1.5 PRO2000
Abdool Karim 2011
McCormack 2010
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 2.22, df = 1 (P = 0.14); I² = 55%
Test for overall effect: Z = 0.68 (P = 0.49)
1.1.6 Tenofovir
Abdool Karim 2010
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 2.34 (P = 0.02)
1.1.7 BufferGel
Abdool Karim 2011
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI)
Total events
Heterogeneity: Chi² = 17.72, df = 13 (P = 0.17); I² = 27%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi² = 9.80, df = 6 (P = 0.13), I² = 38.8%
Events
27
12
48
5
59
151
10
25
35
21
8
29
134
134
36
145
181
38
38
54
54
622
Total
74
139
595
622
376
1806
820
717
1537
1076
1073
2149
3103
3103
769
3326
4095
445
445
775
775
13910
Events
20
16
46
4
45
131
13
16
29
12
9
21
151
151
51
143
194
60
60
51
51
637
Total
64
139
575
619
389
1786
824
708
1532
1077
1069
2146
3099
3099
771
3325
4096
444
444
771
771
13874
Weight
3.4%
2.5%
7.3%
0.6%
6.9%
20.7%
2.0%
2.5%
4.6%
1.9%
1.4%
3.3%
23.7%
23.7%
8.0%
22.4%
30.4%
9.4%
9.4%
8.0%
8.0%
100.0%
M-H, Fixed, 95% CI
1.17 [0.73, 1.87]
0.75 [0.37, 1.53]
1.01 [0.68, 1.49]
1.24 [0.34, 4.61]
1.36 [0.95, 1.95]
1.13 [0.91, 1.40]
0.77 [0.34, 1.75]
1.54 [0.83, 2.86]
1.20 [0.74, 1.95]
1.75 [0.87, 3.54]
0.89 [0.34, 2.29]
1.38 [0.79, 2.41]
0.89 [0.71, 1.11]
0.89 [0.71, 1.11]
0.71 [0.47, 1.07]
1.01 [0.81, 1.27]
0.93 [0.77, 1.14]
0.63 [0.43, 0.93]
0.63 [0.43, 0.93]
1.05 [0.73, 1.52]
1.05 [0.73, 1.52]
0.97 [0.87, 1.08]
Microbicide Placebo Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.05 0.2 1 5 20
Favours Microbicide Favours Placebo
Figure 2 Effectiveness of experimental vaginal microbicides compared to placebo or no intervention for prevention of HIV acquisition
in women. n = number infected: N = total number of participants.
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http://www.biomedcentral.com/1471-2334/12/289of these studies as high. The proportion of participants
lost to follow up was unclear in one nonoxynol-9 study
[19]. The remaining studies had losses to follow-up ran-
ging from 3% to 7% [20,22,25-27]. We have summarised
the risk of bias in included trials in Figure 3.Discussion
To date, 13 randomised controlled trials involving seven
different vaginal microbicides (namely: nonoxynol-9,
SAVVY, cellulose sulphate, carraguard, PRO 2000, Buf-
ferGel and tenofovir) have either been conducted to term
Figure 3 The risk of bias in currently available randomised
controlled trials that have assessed the effect of vaginal
microbicides for prevention of HIV acquisition in women.
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http://www.biomedcentral.com/1471-2334/12/289or stopped early at the recommendation of the respective
data and safety monitoring boards. Overall, the included
studies which enrolled a total of 35,905 HIV-negative
heterosexual women show no evidence of an effect of
vaginal microbicides on the risk of HIV acquisition. The
pooled risk ratio was 0.97 (95% CI 0.87 to 1.08) for
fixed-effect and 0.98 (95% CI 0.86 to 1.12) for random-
effects meta-analysis (I2 = 27%). However, one small
study that enrolled 889 women in South Africa suggests
that a vaginal microbicide containing tenofovir (an anti-
retroviral drug belonging to the class of nucleotide
reverse transcriptase inhibitors) may be effective in redu-
cing the risk of HIV acquisition in heterosexual women.
The relatively small sample size and the small number ofstudy sites may restrict the broad generalisability of the
finding that tenofovir reduces the risk of HIV acquisition
in heterosexual women.
The main strengths of our systematic review are the
comprehensive search for published and unpublished
studies in multiple databases and contact with relevant
organisations and experts, quantitative synthesis of all
currently available data, and sensitivity analyses to inves-
tigate the sensitivity of our findings to the method of
meta-analysis. In general, the Q statistic that we used to
assess for heterogeneity in trial results has low power
when studies included in a meta-analysis have small
sample size or are few in number. This implies that, al-
though a statistically significant result indicates substan-
tial inconsistency in study effects, a non-significant
result does not necessarily mean that there is no hetero-
geneity of effects [11,13]. Therefore to make our findings
more secure, despite the finding of no significant statistical
heterogeneity of effects, we conducted and reported both
fixed- effect and random-effects meta-analyses [12,14]. In
addition, it has been argued that statistical heterogeneity is
inevitable in a meta-analysis; given that there will always be
clinical and or methodological differences (however small)
between studies included in the meta-analysis [13]. We
therefore used the Higgins’ I-squared statistic to quantify
the heterogeneity of intervention effects across included
studies, even though the Q statistic did not detect signifi-
cant statistical heterogeneity. The low I-squared value
(i.e. 27%) reassured us that heterogeneity did not have a
significant impact on the pooled effect estimate [11,13].
To the best of our knowledge, although other microbi-
cide reviews have been conducted [37-42], our review is
the most comprehensive synthesis of existing evidence
on experimental vaginal microbicides for prevention of
HIV acquisition in women. There are substantive differ-
ences between the current systematic review and the
Cochrane review of topical microbicides for prevention
of sexually transmitted infections [42]. Firstly, we have
included all trials of experimental vaginal microbidides
tested to date; but the Cochrane review excluded trials
that assessed the effects of nonoxynol-9. Secondly, the
current review assessed the effects of experimental
microbicides on HIV acquisition while the Cochrane re-
view focused on sexually transmitted infections. Thirdly,
the current review included only studies that enrolled
heterosexual women who were HIV-negative at enrolment
whereas the Cochrane review searched for studies involv-
ing heterosexual women or men who have sex with men
who had no evidence of sexually transmitted infections at
enrolment. Finally, the current review includes a quantita-
tive synthesis of all currently available effectiveness data
from experimental vaginal microbicides; but the Cochrane
review conducted a narrative synthesis of effects across
the different classes of non-nonoxynol-9 microbicides.
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At present, limited evidence suggests that vaginal micro-
bicides containing tenofovir - a nucleotide reverse tran-
scriptase inhibitor - may reduce HIV acquisition in
heterosexual women; but other types of vaginal microbi-
cides have not shown evidence of an effect. Therefore,
there is not enough evidence to recommend vaginal
microbicides for HIV prevention at present. Further ran-
domised controlled trials are needed to confirm the
beneficial effects of the tenofovir gel. In addition, further
research should continue on the development and test-
ing of new microbicides.
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